Analyst: Novo Nordisk's price reductions challenge complex healthcare system

A Sydbank analyst thinks the Danish drugmaker’s lowering of its insulin list prices is ”almost a reckoning with the US healthcare system.” 
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
by marketwire, translated by daniel pedersen

There are numerous reasons why Danish drugmaker Novo Nordisk and some of its pharmaceutical competitors have chosen to lower list prices of certain insulin products substantially. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading

Foto: Corti

AI Act could force innovation to flee Europe

For subscribers